Targeted Disease(s):
Lung Cancer
Purpose of Study:
The escalation part will evaluate the safety, tolerability, PK and recommended dose of expansion (RDE) of oral ABSK-011 in patients with advanced solid tumors. The expansion part of oral ABSK-011 at RDE will be followed for further evaluating safety and tolerability in patients with FGF19 overexpression advanced HCC. Preliminary antitumor activity will also be assessed.
Study Dates:
February 26, 2020 - December 31, 2027
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Abbisko Therapeutics Co., Ltd.
Contact:
Please contact the site directly. All recruiting sites are listed on clinicaltrials.gov.
ClinicalTrails.gov Identifier:
NCT04906434
